Whenever patients are considering peptide therapy, we encourage them to focus on both potential benefits and potential risks
Oral administration of US FDA approved DPP-4 inhibitors, such as Saxagliptin, Vildagliptin, Anagliptin, etc., prolongs the half-lives and thus the action of GLP-1 and GIP, which in turn improves glycemic control with minimal risk of hypoglycemia (Havale and Pal, 2009)
Rybelsus and Wegovy all facilitate weight loss, but to varying degrees
GM has received honoraria for lectures from AstraZeneca and Novo Nordisk
For mothers using formula feeding, resuming semaglutide injections a few weeks after delivery is generally considered safe, though individual timing should be discussed with your OB-GYN
(investor.lilly.com) 11